learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn ORPL
learn zinc PCA
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Sodium PCA
Research
5 / 312 resultsresearch Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review
Anabolic androgenic steroids can increase cancer risk and disrupt hormones.
research Corticotropin releasing hormone and the skin
CRH in the skin acts like the body's stress response system, affecting cell behavior and immune activity.
research Lipid signaling in keratinocytes: Lipin-1 plays a PArt
Lipin-1 is important for skin cell differentiation and skin barrier function.
research VEGF upregulates VEGF receptor-2 on human outer root sheath cells and stimulates proliferation through ERK pathway
VEGF stimulates hair cell growth and increases growth receptor levels through a specific signaling pathway.
research Regulation of pathophysiological and tissue regenerative functions of MSCs mediated via the WNT signaling pathway (Review)
The WNT signaling pathway is crucial for mesenchymal stem cells' function and therapy success.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.